Clinical trial NCT05905588: Study of Hydrogen-rich Water Compared With Placebo in Type 2 Diabetes Patients
Official title: Efficacy and Safety of Hydrogen-rich Water in Subjects With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 2 Diabetes
Keywords: type 2 diabetes mellitus
hydrogen-rich water
Lead sponsor: Qingdao University
Sponsor class: OTHER
Collaborators: name: Qingdao Hiser Medical Group
First posted: 2023-06-15
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of hydrogen-rich water in type 2 diabetes patients.

Detailed description: The objective of the study is to evaluate the efficacy and safety of hydrogen-rich water compared with placebo in patients with type 2 diabetes mellitus after 12-week treatment in a randomized, double-blind, placebo-controlled design.

Eligibility criteria: Inclusion Criteria:

1. Aged 18-75 years old and gender of both sex;
2. Body mass index 18.5kg/m2 to 40 kg/m2;
3. Diagnosed as type 2 diabetes according to the diagnostic criteria of type 2 diabetes established by WHO in 1999;
4. Patients with type 2 diabetes whose blood glucose is not well controlled after diet control and exercise therapy for more than 3 months;
5. HbA1c 7% to 10%, and fasting venous plasma glucose ≤ 15 mmol/L;
6. Be able to understand the procedures and methods of this clinical study, voluntarily participate in and sign the informed consent.

Exclusion Criteria:

1. Type 1 diabetes, gestational diabetes, or other specific types of diabetes;
2. Screening for having received anti-diabetic drug therapy within 3 months or receiving continuous anti-diabetic drug therapy at any time before screening for more than 3 months;
3. History of diabetic ketoacidosis, diabetic hyperglycemic hyperosmolar syndrome, lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;
4. Hyperlipidemia patients with irregular or unstable dose of lipid-lowering drugs;
5. Chronic gastrointestinal disorders with obvious digestive and absorption disorders, as well as other endocrine diseases, such as hyperthyroidism, hypercortisolism, acromegaly, etc.;
6. Patients with diseases that may worsen due to intestinal flatulence (such as Roemheld syndrome, severe hernia, intestinal obstruction, intestinal surgery and intestinal ulcers);
7. Had transient ischemic attack, cerebrovascular accident or unstable angina in the past 6 months; History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery; Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy indicated by ECG;
8. Subjects (taking or not taking antihypertensive drugs) had poor blood pressure control (SBP ≥ 160mmhg, or DBP ≥ 100mmhg);
9. Liver disease, ALT or AST \> 2 ULN, or TBIL \> 2 ULN, and the diagnosis was confirmed within one week;
10. Patients with renal function impairment (Cr \> 1 ULN or Ccr \< 60ml / min) and confirmed by reexamination within one week;
11. Had malignancy in the past 5 years, not including basal cell carcinoma;
12. History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.);
13. Combined use of drugs that affect glucose metabolism, such as glucocorticoids;
14. Combined use of Chinese herbal medicine with the effect of regulating blood glucose within 3 months;
15. Those who have serious diseases and may be in danger of life during treatment and follow-up;
16. Mental and neurological disorders, unable to correctly express their wishes;
17. Alcoholics and drug abusers and addicts;
18. Women of childbearing age are pregnant, breastfeeding, have pregnancy intentions or have a positive pregnancy test (urine HCG or blood HCG), and should not take effective contraceptive measures during the trial (effective contraceptive measures include sterilization, intrauterine device, oral contraceptive or diaphragm method prescribed by local law);
19. Patients who have participated in clinical trials of other drugs or medical devices in the past 3 months;
20. Patients with other diseases that the researchers believe will not be able to evaluate or are unlikely to complete the expected course of treatment and follow-up.

Primary outcomes:
measure: Change in glycosylated hemoglobin (HbA1c)
timeFrame: Baseline and Week 12
Secondary outcomes:
measure: Change in fasting plasma glucose (FPG)
timeFrame: Baseline and Week 12
measure: Change in 2h-postprandial plasma glucose (2h-PPG)
timeFrame: Baseline and Week 12
measure: Patients with HbA1c <7.0%
timeFrame: At Week 12
measure: Patients with HbA1c <6.5%
timeFrame: At Week 12
measure: Change in fasting plasma insulin
timeFrame: Baseline and Week 12
measure: Change in insulin sensitivity and beta cell function assessed by the homeostatic model assessment (HOMA)
timeFrame: Baseline and Week 12
measure: Change in serum lipid profile
timeFrame: Baseline and Week 12
measure: Change in waist circumference
timeFrame: Baseline and Week 12
measure: Change in body weight
timeFrame: Baseline and Week 12
measure: Change in body mass index (BMI)
timeFrame: Baseline and Week 12
measure: Change in blood pressure
timeFrame: Baseline and Week 12
measure: Change in oxidative stress index and inflammatory index
timeFrame: Baseline and Week 12
measure: Number of participants with adverse events as a measure of safety and tolerability
timeFrame: Baseline to Week 12
Other outcomes:
Locations:
city: Qingdao
country: China
facility: Qingdao Traditional Chinese Medicine Hospital
state: Shandong
Study officials:
affiliation: Qingdao Universtiy
name: Tongshang Ni, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: